According to committee chairman Rick Scott (R-FL), "inconsistent review practices, shifting standards, and redundant, ...

However, traditional clinical trial designs are often ill-suited for rare disease research with common challenges including ...

The IPO, which saw 25 million shares sold at $16, in the middle of the $15 to 17 range predicted by the company, continues a ...

Oxford-based Sitryx, which also has operations in Boston in the US, was founded in 2018 with seed funding from SV Health ...

Eli Lilly's oral GLP-1 agonist orforglipron was more effective than Novo Nordisk's recently launched Wegovy pill in a head-to ...

A recent study found that up to 40% of trials might be untrustworthy due to flaws in design, improper data collection, and ...

Asahi Kasei has agreed a €780 million (around $920 million) price tag for Wuppertal-based Aicuris, which is hoping for FDA ...

As Rare Disease Day approaches, the lessons from recent European launches are clear: success comes from disciplined operating models, disease‑centred engagement, pragmatic evidence strategies, and ...

Since 2021, the story of GLP-1s has illustrated that scientific progress is rarely a straight line from hypothesis to patient ...

The manufacturing of GLP-1s involves a complex process that includes peptide synthesis, amino acid coupling, cleavage, purification, and chemical modifications. The solid-phase peptide synthesis (SPPS ...

Eisai has a position in kidney cancer with Lenvima (lenvatinib), a kinase inhibitor that is approved for use in combination with MSD's cancer immunotherapy Keytruda (pembrolizumab) as a first-line ...

As Rare Disease Day approaches, in a special episode of the pharmaphorum podcast, sponsored by AOP Health, we spoke with Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, at AOP ...